

# Strategy for Enabling Clinical Confidence in Breath Analysis

#### Farrow-Dunn FM, Hodnett M, Worton DR

National Physical Laboratory, Hampton Road, Teddington, Middlesex, TW11 0LW, UK fred.farrow-dunn@npl.co.uk

#### Abstract

Breath analysis is an exciting and innovative field that has demonstrated potential to dramatically increase survival rates by detecting diseases at earlier stages when treatment options are more effective, as well as enabling better management of chronic illnesses improving the health span of patients.

However, there is a lack of understanding and commercially available solutions needed to achieve reproducible and reliable data within the breath analysis community. This results in poor data comparability, inhibiting this important innovation from realising its full potential [1,2].

- Traceable and accurate quantification are key to underpinning data comparability and data confidence.
- Traceability and accuracy are ensured through calibration using primary reference materials, developed, maintained and disseminated by National Metrology Institutes like NPL.

NPL's expertise in gas metrology and standardisation can be repurposed for the medical sector to accelerate the uptake of breath analysis into routine clinical practice.

### The need for early diagnostic tools

- Early-stage diagnosis is one of the most important factors affecting patient outcomes, particularly for diseases such as cancer.
- Providing new diagnostic techniques to enable earlier detection will support the NHS Long Term Plan goal of saving 55,000 lives per year by early detection of cancer [3].

### Breath analysis for early disease diagnostics

- The breath analysis market has grown exponentially over the last two decades, as evidenced by the increase in peer reviewed publications and the number of clinical trials involving breath analysis [6].
- This hasn't translated into routine clinical practice
- Poor data comparability resulting in a lack of clinical confidence is a contributing

#### A colorectal cancer case study demonstrates the need for early diagnosis [4,5].





**Figure 1.** Incidence and survival of cancer cases by stage at diagnosis. 1-year survival rate more than doubles from 44 % to 98 % when diagnosed at stage 1 compared to stage 4. *Based on a graphic created by Cancer Research UK.*  **Figure 2.** Cost per patient by number of years after diagnosis. Stage 3 and 4 diagnosis have an increased cost when compared to stage 1 and 2 diagnosis for each year after diagnosis.

#### factor [1,2] which NPL is perfectly positioned to address.



**Figure 3.** Number of hits in a PubMed search for "breath analysis disease detection" between 2004 and 2024 showing an increase in publications over the last two decades.



**Figure 4.** Number of clinical trials between 2004 and 2024 showing an increase in clinical trials over the last two decades. *Credit: Owlstone Medical* 

## Recent work at NPL

NPL delivered a Government Office of Technology Transfer Knowledge Asset Grant Fund (GOTT KAGF) project which engaged with academic and industrial stakeholders to review the barriers that negatively impact data comparability and clinical confidence in the breath analysis industry. The common findings from the stakeholder engagement are as follows:

- There is a lack of breath-specific reference materials available commercially.
- Regulatory bodies often do not know what criteria are needed to certify new breath analysis technologies.
- Breath is a challenging matrix to measure with the biomarkers of interest typically being present at low concentrations (nmol / mol or pmol / mol) compared to other compounds commonly found in exhaled breath (µmol / mol) [7].
- Patient to patient variability and contamination from exogeneous sources make identifying and quantifying biomarkers relevant to specific diseases very challenging.

#### Strategy for Enabling Clinical Confidence



NPL have developed an implementation strategy to exploit the findings from the GOTT project. This involves repurposing our Knowledge Assets in the following areas to maximise impact in the breath analysis community:

- Expertise in the development, preparation, analytical validation, control, dissemination and use of traceable gas reference materials that includes a wide range of volatile organic compounds (VOCs) and inorganic gases relevant to breath analysis.
- Expertise in considerations for accurate sampling and analysis of trace components in gas materials.
- Expertise in driving and delivering the development of international consensus such as through CEN and ISO standardisation committees.
- Expertise in the development and operation of interlaboratory comparison exercises, participation in which is essential for institutions wanting to demonstrate their capabilities against internationally recognised standards.

**Figure 5.** Implementation strategy developed by NPL in accelerate the uptake of breath analysis into routine clinical practice.

#### References

- [1] Anders, C., Jesper Rømhild, D., Ingrid, T., Jørgen, V., and Jan, B.: A systematic review of breath analysis and detection of volatile organic compounds in COPD, Journal of Breath Research, 10, 034002, 2016.
- [2] Hanna, G. B., Boshier, P. R., Markar, S. R., and Romano, A.: Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysisAccuracy and Challenges of VOC-Based Exhaled
- Breath Tests for Cancer Diagnosis Accuracy and Challenges of VOC-Based Exhaled Breath Tests for Cancer Diagnosis, JAMA Oncology, 5, e182815-e182815, 10.1001/jamaoncol.2018.2815, 2019.
- [3] https://www.longtermplan.nhs.uk/wp-content/uploads/2019/01/the-nhs-long-term-plan-summary.pdf
- [4] https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/
- [5] Laudicella M., Walsh B., Burns E., Smith P.C.: Cost of care for cancer patients in England: evidence from population-based patient-level data: British Journal of Cancer, May 2016, doi: 10.1038/bjc.2016.77
- [6] https://www.owlstonemedical.com/about/blog/2018/dec/07/breath-analysis-clinical-trials/
- [7] Moura P.C., Raposo M., Vassilenko V.: Breath biomarkers in Non-Carcinogenic diseases, Clinica Chimica Acta, Vol 552, January 2024, 117692, doi: 10.1016/j.cca.2023.117692

